Macugen Advisory Committee To Discuss Concomitant Use With Visudyne
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will discuss concomitant use of Pfizer/Eyetech's Macugen and Novartis/QLT's Visudyne (verteporfin) at an Aug. 27 meeting
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will discuss concomitant use of Pfizer/Eyetech's Macugen and Novartis/QLT's Visudyne (verteporfin) at an Aug. 27 meeting